CTRI/2014/09/005062已完成3 期
EVALUATION OF EFFICACY AND SAFETY OF TWO FIXED DOSE COMBINATION OF CARBONIC ANHYDRASE INHIBITOR AND BETA BLOCKER FOR THE TREATMENT OF ELEVATED INTRAOCULAR PRESSURE IN PATIENTS WITH OCULAR HYPERTENSION OR OPEN-ANGLE GLAUCOMA: A RANDOMIZED, OPEN LABEL, COMPARATIVE, MULTICENTRIC STUDY
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male/Female patients aged between 18-75 years.
- •2.Patients diagnosed with Primary Openâ??angle glaucoma.
- •3.Patients with IOP of 24-36 mm Hg of affected eye(s).
- •4.New Patients or Patients who are on mono-therapy of either CAIs or Beta-blockers or any other IOP-lowering therapy not adequately controlled.
- •5.Patients who have given their informed consent.
排除标准
- •1.Pregnant or lactating women and women of childbearing potential who are not using contraceptives.
- •2.Patients with a history of allergic hypersensitivity to oral or topical CAIs, Beta-blockers, sulfonamide drugs, or any components of these medications.
- •3.Patients with acute or chronic conjunctivitis.
- •4.Patients with uncontrolled hypertension, dry eye syndrome, diabetic retinopathy, hyperchloraemic acidosis and insulin dependent diabetes.
- •5.Patients undergone intraocular surgery or laser surgery within the past 3 months.
- •6.Patients currently using any systemic corticosteroid, or is having had therapy with any investigational agent within past 30 days.
- •7.Patients with severe, unstable, or uncontrolled cardiovascular or pulmonary disease.
- •8.Patients with history of hematologic disorders other than mild anemia.
- •9.History of non-compliance to medical regimens or those patients unwilling to comply with the study protocol.
研究者
相似试验
进行中（未招募）
不适用
Efficacy, safety and tolerability of two Fixed-Dose Combinations of Aclidinium bromide with two doses of Formoterol fumarate compared with Aclidinium bromide, Formoterol fumarate and placebo all administered twice daily in stable, moderate to severe Chronic Obstructive Pulmonary Disease patients.Moderate to severe chronic obstructive pulmonary disease (COPD)MedDRA version: 12.0Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2009-015901-38-HUALMIRALL, S.A.120
进行中（未招募）
不适用
Efficacy, safety and tolerability of two Fixed-Dose Combinations of Aclidinium bromide with two doses of Formoterol fumarate compared with Aclidinium bromide, Formoterol fumarate and placebo all administered twice daily in stable, moderate to severe Chronic Obstructive Pulmonary Disease patients.Moderate to severe chronic obstructive pulmonary disease (COPD)MedDRA version: 12.0Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2009-015901-38-DEALMIRALL, S.A.120
进行中（未招募）
不适用
Efficacy, safety and tolerability of two Fixed-Dose Combinations of Aclidinium bromide with two doses of Formoterol fumarate compared with Aclidinium bromide, Formoterol fumarate and placebo all administered twice daily in stable, moderate to severe Chronic Obstructive Pulmonary Disease patients.EUCTR2009-015901-38-CZALMIRALL, S.A.120
进行中（未招募）
1 期
Efficacy, safety and tolerability of two Fixed-Dose Combinations of Aclidinium bromide with two doses of Formoterol fumarate compared with Aclidinium bromide, Formoterol fumarate and placebo all administered twice daily in stable, moderate to severe Chronic Obstructive Pulmonary Disease patients.Moderate to severe chronic obstructive pulmonary disease (COPD)MedDRA version: 12.0Level: LLTClassification code 10009033Term: Chronic obstructive pulmonary diseaseEUCTR2009-015901-38-ROALMIRALL, S.A.120
已完成
不适用
A STUDY OF THE EFFICACY AND SAFETY OF MULTIPLE DOSES OF DUTASTERIDE VERSUS PLACEBO AND FINASTERIDE IN THE TREATMENT OF MALE SUBJECTS WITH ANDROGENETIC ALOPECIA-L64L64PER-063-10GLAXOSMITHKLINE PERU S.A.,103